INCHEON, South Korea - Friday, 23. February 2024
- Results of the two-year LIBERTY studies demonstrate that CT-P13 SC provides long-term clinical benefits and safety, with the convenience of subcutaneous (SC) administration, in the treatment of moderately to severely active CD and UC1,2